Vitrase market seen growing on diabetes, eye disease demand
The Business Research Company says the Vitrase market is expanding on stronger demand for injectable therapies, rising diabetes cases, and more eye disease treatments. North America led the market in 2025, while Asia-Pacific is expected to be a major growth region.
Why it matters: - Vitrase demand is rising as more injectable therapies move into routine use across ophthalmology and other specialties. - The market benefits from growth in diabetes care, where Vitrase supports treatment of vitreous hemorrhages and improves absorption of injected medicines. - The report points to a wider shift toward enzyme-assisted drug delivery and better patient comfort during injections.
What happened: - The Business Research Company released its Vitrase Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Vitrase market is growing on advances in drug delivery and expanding clinical applications. - The report says North America was the largest regional market in 2025. - The report says Asia-Pacific offers major growth opportunities because of healthcare infrastructure expansion and higher rates of diabetes and eye disorders. - The company also published sample and full-report links for the study: Download a free sample and View the full report.
The details: - Vitrase is a hyaluronidase-based enzyme that helps disperse and absorb injected drugs and fluids. - The enzyme breaks down hyaluronic acid in connective tissue, which improves subcutaneous and intramuscular drug delivery. - Historic growth was driven by broader use of injectable drug therapies, enzyme purification improvements, wider clinical adoption, and better understanding of connective tissue modulation. - Forecast growth is expected to come from demand for optimized drug delivery systems, more injectable biologics, enzyme-assisted delivery technologies, improved injection comfort, and broader use in specialized medical treatments. - Emerging trends include hyaluronidase-enhanced injections, stronger demand for drug dispersion agents, more use in oncology and ophthalmology, combination injection therapies, and a focus on injection efficiency. - The report says the growing number of people with diabetes is a major driver. - The report cites UK data showing a 22% increase in type 1 diabetes patients receiving all recommended care processes from March 2022 to March 2023, while type 2 diabetes patients increased by 21%; the share reaching target HbA1c levels hit 37.9%. - The report says rising eye disease rates are also supporting demand, including cataracts, glaucoma, diabetic retinopathy, and macular degeneration. - The report cites a September 2024 Guardian estimate that myopia may affect more than one in three children and teenagers globally and could exceed 740 million cases by 2050. - The report says higher healthcare spending supports Vitrase use by boosting access to advanced ophthalmic surgery and reimbursement coverage. - Eurostat data cited in the report shows healthcare spending in the European Union reached about $1,866 billion (€1,720 billion) in 2023, or 10% of GDP, with Germany at $533 billion (€492 billion).
Between the lines: - The market story is less about one drug and more about the broader expansion of enzyme-enabled delivery systems. - Diabetes and eye disease are acting as demand anchors because Vitrase fits treatment paths that rely on injections and ophthalmic procedures. - The report’s regional split suggests mature markets are driving current revenue, while emerging markets are shaping the next wave of growth.
What's next: - The report expects continued growth through 2035 as injectable biologics, specialty procedures, and delivery technology improve. - Asia-Pacific could narrow the gap with North America if healthcare capacity and diagnosis rates keep rising. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspots infographics, and updated graphics and tables.
The bottom line: - Vitrase is being pulled by rising diabetes and eye disease burden, while its growth case rests on broader demand for more efficient injectable drug delivery.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
German Health Review
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.